Showing results (231-240 of 277) with videos related to
Sort By:
Pageof 28
Haematologica|September 5, 2024
Loncastuximab tesirine in Chinese patients with relapsed or refractory diffuse large B-cell lymphoma: a multicenter, open-label, single-arm, phase II trialNingjing Lin, Xiuhua Sun, Hui Zhou, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2025
Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell LymphomaMichael Wang, David Salek, David Belada, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 8, 2024
Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell Lymphoma: Data from the First-in-Human Phase I StudyYuqin Song, Zhengming Jin, Zhi-Ming Li, et al.Blood Advances|August 14, 2025
Phase 2 Study of Relmacabtagene Autoleucel (CD19 CAR-T) for Relapsed/Refractory Mantle Cell Lymphoma in Chinese AdultsYan Xie, Keshu Zhou, Lanfang Li, et al.Future Oncology (London, England)|April 7, 2020
ENGINE: a Phase III randomized placebo controlled study of enzastaurin/R-CHOP as frontline therapy in high-risk diffuse large B-cell lymphoma patients with the genomic biomarker DGM1Grzegorz S Nowakowski, Jun Zhu, Qingyuan Zhang, et al.Journal of Hematology & Oncology|October 15, 2021
Zanubrutinib monotherapy in relapsed/refractory mantle cell lymphoma: a pooled analysis of two clinical trialsKeshu Zhou, Dehui Zou, Jianfeng Zhou, et al.Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|February 22, 2023
Clinical characteristics and outcomes of follicular lymphoma patients with extranodal involvement: analysis of a series of 1090 cases in ChinaZhijuan Lin, Jie Zha, Shuhua Yi, et al.Cancer Medicine|September 14, 2023
Long-term outcomes of second-line versus later-line zanubrutinib treatment in patients with relapsed/refractory mantle cell lymphoma: An updated pooled analysisYuqin Song, Keshu Zhou, Dehui Zou, et al.Advances in Therapy|July 28, 2022
Zanubrutinib Monotherapy for Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Pooled Analysis of Three StudiesWei Xu, Shenmiao Yang, Constantine S Tam, et al.Journal of Hematology & Oncology|August 24, 2021
Clinical features and outcomes of 1845 patients with follicular lymphoma: a real-world multicenter experience in ChinaJie Zha, Liyuan Fan, Shuhua Yi, et al.Pageof 28